

**Note:** Page references followed by an ‘f’ refer to Figures; those followed by a ‘t’ refer to Tables.

- A and B subgroups. *See* Blood groups
- Abbreviated (ABO) crossmatch, 221–222
- ABH genes, 177f, 179t
- ABO and Rh  
in platelet transfusion, 268–270  
typing, 218, 219t
- ABO antigens, 219t, 235–236
- ABO incompatible transplants, 319–322, 320f, 320t
- ABO system, 174–181, 178t, 179t
- ABO typing, 149–151, 151t, 152t  
discrepancies, causes of, 152t
- Acetaminophen, 384
- Acid base balance, 313
- Acid base imbalance, 400
- Acid citrate dextrose (ACD), 78, 503
- Acidosis, 336
- Acquired immune deficiency syndrome (AIDS), 279, 476–477, 480  
*See also* Transfusion therapy
- Activated natural killer cells, 505
- Active bleeding, treatment of, 265–268, 267f
- Acute blood loss, 305t  
*See also* Transfusion therapy
- Acute chest syndrome, 91
- Acute lung injury (ALI), 385–387, 386t
- Acute lymphocytic leukemia (ALL), 505
- Acute myelogenous leukemia (AML), 505
- Acute normovolemic hemodilution (ANH), 103, 110–112, 111t, 112t
- Additive solutions, 70t
- Adenosine triphosphate (ATP), 8, 69
- Adoptive immunotherapy, 504–7  
antiviral immunotherapy, 506  
cytomegalovirus, 506  
dendritic cells, 505–506  
Epstein–Barr virus  
lymphoproliferative disorders, 506–507  
natural killer and activated natural killer cells, 505  
peripheral blood mononuclear cells, 505  
T regulatory cells, 504–505
- Adsol, 252
- Adsorbance measurement, 233
- Adsorption columns, 548–550
- Adult respiratory distress syndrome (ARDS), 314, 401, 542
- Adult T cell leukemia (ATL), 423–424
- Affinity column, 215

- Albumin, 538–539
- Alcohol, 52
- Allergic reactions, 385
- Alloantigens, 185, 201
- Allogeneic bone marrow
  - transplantation, 284
- Allogeneic hematopoietic stem cell
  - transplantation, 459–460
- Allogeneic transfusion, 103, 106
- Alloimmune platelet refractoriness, 463, 533
- Alloimmunization, 75, 76, 82, 201, 268, 272f, 461
  - prevention, 270, 274
- ALT. *See* Alanine aminotransferase (ALT)
- America's Blood Centers (ABC), 21–22
- American Association of Blood Banks (AABB), 18, 20–21, 115, 153, 231, 250
  - Quality program, 563t, 565–9
- American Instrument Company, 125
- American Medical Association (AMA), 4, 521
- American Red Cross, 21, 34, 425
  - Rare Donor Registries, 231, 250, 345
- American Society of Hematology, 20
- Aminco Celltrifuge, 125
- Amino acid, 451
- Amyotrophic lateral sclerosis (ALS), 530
- Anaphylactic reactions, 387
- Anemia
  - in AIDS, 340
  - aplastic, 262
  - of chronic disease, 475–476
  - physiologic responses to, 243t
  - of prematurity, 477
  - preoperative, detection and management, 102–3
- Angiotensin converting enzyme (ACE) inhibitors, 543–544
- Animal to animal transfusions, 2
- Antibody
  - of ABH system, 181
  - platelet specific, 166
  - to red cell antigens, 195–196, 196t
  - screening test, 221t
- Anticoagulant citrate dextrose (ACD), 59, 128
- Anticoagulant, 4–5, 59, 113
  - preservative solutions, 50, 69, 69t, 70t
- Antigen antibody reaction
  - detection, 211
  - affinity column, 215
  - gel test, 214
  - slide/tile typing, 214
  - solid phase tests, 214
  - tube tests, 215
- Antigen antibody reaction
  - enhancement, 212
  - antihuman globulin (AHG)
    - serum, 212
  - enzymes, 213
  - low ionic strength solution (LISS), 213
  - polybrene, 213
  - polyethylene glycol (PEG), 213
- Antigen presenting cells (APC), 448
- Antigens, 166
  - detection tests, 428
  - distribution and subgroups, 180
- Antiglobulin serum, 6–7
- Anti HIV-1 positive blood
  - transfusion, 422
- Anti HIV negative blood (window phase) transfusion, 421
- Antihuman globulin (AHG), 152, 154, 212, 220f
- Antitumor immunotherapy, 506
- Antiviral immunotherapy, 506
- Apheresis donors
  - adverse reactions in, 58, 58t
  - air embolus, 59–60
  - anticoagulation, 59
  - circulatory effects, 59
  - citrate toxicity, 59
  - hematoma, 60
  - leukapheresis, complications
    - in, 61
  - lymphocyte depletion, 60–61
  - mechanical hemolysis, 60
  - mononuclear cell apheresis, complications in, 62
  - plasmapheresis, complications in, 61
  - platelet depletion/damage, 60
  - vasovagal reactions, 59
- medical assessment of
  - allogeneic donors, 58
  - blood volume shifts, 57

- Apheresis donors (*cont'd*)
- physical examination of, 58
  - plateletpheresis donors, 56
  - red cell loss, 56
  - serial donations, complications of, 57–58
  - recruitment of, 36
- Apheresis, 9
- platelets, 262
  - procedure, 543–544
- Apheresis, component production by, 122–123, 124t
- centrifugation instrument for cytapheresis
    - continuous flow centrifugation, 125–126
    - intermittent flow centrifugation, 123–125
  - cytapheresis, 135–140, 137t, 138t, 139f (*See also* Peripheral blood stem cells (PBSC))
  - instruments
    - Fresenius Kabi Alyx, 127
    - Fresenius Kabi Amicus, 126–127
    - Fresenius Kabi AS, 104, 129
    - Haemonetics system, 128–129, 128f
    - Terumo Trima Accel™, 127–128
  - leukapheresis, 131–132
    - donor–recipient matching, 134
    - filtration leukapheresis (FL), 133
    - granulocytes, function of, 133
    - granulocytes, storage of, 133–134
    - hydroxyethyl starch in, 132
    - stimulation of donors with corticosteroid or G-CSF, 132–133
  - lymphocytapheresis, 134–135
  - plateletpheresis, 129–130
  - red cell collection, 130–131, 131t
  - See also* Therapeutic apheresis
- Aplastic anemia, 262, 285, 480
- Arterial puncture, 55
- Arthur D. Little Corporation (ADL), 123
- Attribution/self perception framework, 30
- Audit
- internal quality, 568
  - transfusion, 573–574
- Autoantibodies, 336
- Autoimmune diseases, 507
- Autoimmune hemolytic anemia (AIHA), 322, 339t, 533
- Autoimmune neutropenia (AIN), 345
- Autoimmune thrombocytopenia, 201, 262, 342–343, 533
- Autoimmune thrombocytopenic purpura, 87, 267
- Autologous blood donation, preoperative, 103–106, 104t
- acute normovolemic hemodilution (ANH), 103, 110–112, 111t, 112t
  - postoperative salvage, 103, 114–15
- Autologous bone marrow transplantation, 284
- Automated testing systems for infectious disease, 157t
- Babesia bovis*, 429
- Babesia microti*, 165, 429
- Babesiosis, 165, 429, 535
- BacT/ALERT system, 164
- Bacteremia, 114
- Bacteria, detection of, 164–165
- Bacterial contamination, transfusion transmitted, 389–91, 390t
- Bacterial infections. *See* Transfusion transmitted diseases
- Baxter Corporation, 7
- Baxter CS 3000, 126
- Becker's model of commitment, 30
- Bilirubin, 211
- Bleeding prevention. *See* Prophylaxis
- Bleeding tendency, 400
- Blood banking and transfusion medicine, 5
- components produced by, 68t
  - errors in transfusion medicine, 569–570
  - procedures, 306–307, 413t
  - quality assurance in transfusion therapy, 570–4
  - audit, transfusion, 573–574
  - blood management programs, 573
  - blood ordering practices, 573
  - blood supply, 570t, 571
  - hospital transfusion service, 571–572, 571t
  - medical indications, 573
  - physician education, 574

- quality assurance in patient therapy, 572
  - transfusion committee, 574
  - transfusion procedures, 572
- quality systems in blood supply
  - adverse reaction files, 568
  - American Association of Blood Banks Quality program, 565–569
  - computers and information systems, 567
  - critical control points, 569
  - customer focus, 566
  - documents and records, 566
  - equipment, 566
  - facilities work environment and safety, 565–566
  - human resources, 566–567
  - internal quality audits, 568
  - International Organization for Standardization, 564
  - labeling, 566
  - laboratory quality controls, 569
  - nonconforming event management, 567
  - organization and leadership, 565
  - process improvement, 568
  - records management, 567
  - standard operating procedures (SOPs), 568
  - supplies and material management, 566
- quality and quality assurance systems, 560–564, 561t, 562t, 563t, 564t
- quality assurance in blood supply system, 564–569
- Blood cell separators, 122
- Blood collection, 51–52
  - amount, 16–18
  - Containers, 49, 50
  - cord, 503–504
  - whole, 41–42, 49–52
- Blood components, 7–8
  - blood substitutes, 90–91
    - hemoglobin substitutes, impact of, 90–91
    - potential clinical uses, 91
  - identification, 365–366, 366t
  - irradiation of, 82, 281–282
  - outline of, 67, 68t
  - pathogen inactivated, 87
    - fresh frozen plasma (FFP), 87–88
    - platelets, 88–89
    - red cells, 89
    - solvent–detergent plasma (Octoplas), 87, 88t
    - universal red cells, 89–90
  - preparation from whole blood
    - anticoagulant–preservative solutions, 69, 70t, 71t
    - blood processing, 69–71, 71f
    - cryoprecipitate, 78–79
    - fresh frozen plasma (FFP), 77–78
    - frozen or deglycerolized red blood cells, 73–75
    - granulocytes, 82
    - 24 hour frozen plasma (FP24), 77
    - leukocyte reduced red blood cells, 75–77, 76t
    - plasma, 78
    - platelet concentrates (whole blood), 79–82, 79t, 80f
    - red blood cells, 72–73, 72t
    - washed red cells, 75
  - utilization, 320t
- Blood components, clinical uses of
  - blood component therapy, 242
  - cytomegalovirus safe blood components, 276–280
    - acquired immune deficiency syndrome (AIDS), 279
    - bone marrow transplantation, 278–279
    - chemotherapy, extensive, 280
    - heart/heart–lung/liver/pancreas transplantation, 279
    - kidney transplantation, 277–278
    - neonates, 277
    - pregnant women, 277
    - severe combined immune deficiency (congenital), 279–280
  - irradiated blood components
    - graft versus host disease (GVHD), 281–282
    - indications for, 284–7
    - irradiation, 281–282
    - leukocyte depletion, 283
    - pathogen inactivation and prevention of GVHD, 283–284
    - quality control of irradiation, 283

- Blood components, clinical uses
  - of (*cont'd*)
  - storage of, 282–283
- therapeutic agents containing
  - coagulation factors
  - ABO and Rh in platelet transfusion, 268–270
  - bleeding (prophylaxis)
    - prevention, 265–268, 267f, 271–274, 272f, 273t
  - blood group compatibility, 262
  - crossmatching for platelet transfusion, 272–273
  - cryoprecipitate, 254–255
  - fibrinogen, 261
  - fibrin sealant (glue), 255, 256t, 257t
  - fresh frozen plasma (FFP), 252, 253, 253t, 257–258
  - 24 hour plasma (FP 24), 252, 253
  - multiple coagulation factors,
    - deficiency of, 255–259
  - plasma, 254
  - prophylaxis for invasive procedures, 268
  - single coagulation factors,
    - deficiency of, 259–262
  - solvent–detergent plasma, 254
- transfusion of components
  - bloodless medicine, 245, 245t
  - frozen deglycerolized red blood cells, 250
  - leukocyte reduced red cells, 247–249, 247t, 248t
  - physiology in red cell transfusion
    - decisions, 242–244, 243t
  - red blood cell components, use of, 246–250
  - red blood cell transfusion, effects of, 251–252
  - red blood cell transfusion trigger, 244–245
  - red cells, clinical uses of, 246
  - stored red blood cells, clinical effects of, 246
  - washed red cells, 249–250
  - whole blood, 247
- Blood donation
  - by infectious patient, 108–109
  - directed donors, 115, 116
  - patient specific, 116
  - severe reactions to, 54
  - See also* Preoperative autologous donor blood
- Blood donor medical assessment
  - apheresis donors
    - adverse reactions in, 58–62
    - medical assessment of, 42, 42t, 55–58
  - whole blood, collection of
    - anticoagulant preservative solutions, 50
    - blood collection, 51–52
    - blood containers, 49–50
    - labeling, 49
    - vein selection, 50
    - venipuncture, 51
    - venipuncture site preparation, 50, 50t
  - whole blood donation, adverse reactions to, 52–55, 53t
    - arterial puncture, 55
    - hematoma, 55
    - nerve injuries, 54
    - postdonation care, 52
    - seizures, 54
    - severe reactions to blood donation, 54
    - therapeutic bleeding, 55
    - thrombosis, 55
  - whole blood donors, medical
    - assessment of, 42, 42t
    - hemochromatosis patients as blood donors, 47
    - medical history, 43–47, 44–45t
    - physical examination of blood donor, 47–49
    - registration, 42–43
    - special blood donations, 49
- Blood donors
  - hemochromatosis patients as, 47
  - medical history questions for, 44–45t
- Blood donors, recruitment of
  - apheresis donor recruitment, 36
  - bone marrow donors, 36–37
  - demographic characteristics of
    - age, 29
    - education and socioeconomic characteristics, 29
    - employment, 30
    - gender, 28–29

- race/ethnicity, 29
  - social characteristics, 30
- donation experience, 32
  - donation situation, 33
  - family history of donation, 33
  - incentives, role of, 34
  - organizational influences, 33–34
  - social influences on blood donation, 32–33
- whole blood donor recruitment strategies, 34–35
- whole blood donors, motivation of, 31
  - integrated model, 30–31
  - planned behavior theory, 31
  - psychosocial theories, 30
  - reasons for donation, 31
- Blood groups**
  - ABO system, 174–181, 178t, 179t
    - genes and composition, 177–179
  - antibodies, 324
  - antibodies to red cell antigens, 195–196, 196t
  - A and B subgroups, 179–180
  - antibodies of ABH system, 181
  - antigen distribution and subgroups, 180
  - Bombay type, 180
  - compatibility, 262
  - discovery of, 4, 181–182
  - granulocytes, 204–206, 205t
  - laboratory detection of (*See* Laboratory detection of blood groups)
  - molecules, function of, 196, 198, 199t
    - complement regulatory molecules, 199–200
    - enzymatic activity, 200
    - microbial receptor, 200
    - receptors and adhesion molecules, 198–199
    - red cell function, 198, 199t
    - red cell structure, 197–198, 198t
    - transport protein, 199
  - platelets, 200–204, 202–203t, 204t
  - red cell blood groups, 173, 174t, 175–176t, 177f, 178f
  - Catwright (Yt), 192
  - Colton (Co) system, 192
  - Cromer (Cr) system, 193
  - Diego (Di) system, 191–192
  - Dombrock (Do) system, 192
  - Duffy system, 186–187
  - Gerbich (Ge) system, 193
  - GIL antigen, 194
  - Ii blood group antigens, 194–195
  - Indian (In) system, 193–194
  - JMH system, 194
  - Kell system, 185–186
  - Kidd system, 187
  - Knops (Kn) system, 193
  - Lewis system, 190–191
  - Lutheran system, 188
  - LW system, 191
  - MNSs system, 188–189
  - OK system, 194
  - P system, 189–190
  - RAPH system, 194
  - Rogers (Rg) and chido (Ch) system, 193
  - Scianna (Sc) system, 192
  - Xg system, 192
- Rh system**
  - antibodies, 184, 185t
  - discovery, 181–182
  - nomenclature and genetics, 182, 183t
  - null type, 184
  - structure and composition of D antigen, 182–183
  - weak D, D variant, Du, and partial D, 182–183
  - see also* Human leukocyte antigens (HLA)
- Blood Safety and Clinical Technology**, 22
- Blood salvage**
  - intraoperative, 112–114, 113t
  - postoperative, 114–115
- Blood supply**, 570t, 571
  - availability, 226–228, 227t, 230
  - and safety, 14t
  - blood sharing, 18
  - community blood centers, activities of, 18–19
  - nongovernmental blood bank organizations
    - American Association of Blood Banks (AABB), 20–21
    - America's Blood Centers (ABC), 21–22

- Blood supply (*cont'd*)
- Federation of Red Cross and Red Crescent Societies, 22
  - International Society for Blood Transfusion (ISBT), 22–23
  - Plasma Protein Therapeutics Association (PPTA), 22
  - World Health Organization (WHO), 22
- plasma collection system
- federally licensed, 20
  - plasma, definitions of, 19
  - plasma collection activity, 20
- regulation of
- CAP accreditation program, 25–26
  - licensure, 25
  - United States Federal Regulation, 23–25
  - voluntary accreditation of blood banks, 25
  - worldwide, 13–15, 14t
- Blood transfusion, techniques of, 361t
- blood administration sets and filters, 363–364
  - blood component identification, 365–366, 366t
  - blood sample for compatibility testing, 361–362
  - for children and neonates, 370–371
  - consent, obtaining, 360–361
  - hematopoietic stem cell products, 371–373, 372t
  - infusion pumps, 369
  - infusion solutions, 365
  - in nonhospital setting, 373
  - nursing care of patients, 369–370
  - patient identification, 365–366, 366t
  - platelets and plasma, 371
  - rate and duration of, 367
  - transfusion, start of, 366–367
  - venous access and venipuncture, 364
  - warming of blood, 367–368, 368t
- Blood sampling
- for compatibility test, 361–362
  - identification of, 217
  - for laboratory tests, 314
- Blood use monitoring, 102
- Bloodless medicine, 245, 245t
- Blundell, James, 3
- Bombay phenotype, 180
- Bone marrow, 498–9, 499t
- collection, 496–7
  - donors, 36–37
  - transplantation (BMT), 278–279, 477, 500
- Borrelia burgdorferi*, 429
- Bovine spongiform encephalopathy (BSE), 430–431
- Boyle, Robert, 2
- Bradycardia, 53
- Bradykinin (BK), 381, 388, 544
- Buffy coat (BC) methods of platelet preparation, 80–1, 80f
- Bystander immune hemolysis, 335
- Cadaver blood, 5–6
- Canadian Apheresis Study Group, 542
- Canisters, 113
- CAP accreditation program, 25–26
- Carbohydrates, 173
- Cardanus, Hieronymus, 1
- Cardiac arrhythmia, 314
- Cardiovascular surgery, transfusion therapy, 314–316
- Caridian Spectra, 136
- Catastrophic antiphospholipid syndrome (CAPS), 532
- Catwright (Yt) system, 192
- CD34+ cell yield in PBSC, 139f
- CD44, 199
- Cell lysis, 452
- Cell processing devices, 113
- Cellular assays, 453
- Cellular engineering
- activation, 501
  - cell depletion
    - red cells, 500
    - T lymphocytes, 500
    - tumor cell purging, 500
  - engineered cells, clinical uses of, 492, 493t
  - ex vivo production of red cells, 501–502
  - expansion, 501
  - hematopoietic progenitor, 492–500, 494t, 494–5t, 499t
  - marrow collection, 496–497
  - mesenchymal stem cells (MSCs), 507
  - myocardial repair, 507

- new blood components,
  - development and production of, 492–493, 493t
- positive selection, 501
- quality assurance, 509–511
- regulation of, 508–509
- stem cell
  - collection, 497
  - preservation, 497–8
  - products, 498–500, 499t
  - sources of, 494–495, 495t, 496t–497t
  - See also under* Hematopoietic stem cells
- transduction, 501
- umbilical cord blood banking, 502–504, 502t
- Central nervous system leukostasis, 545
- Central venous catheters, 536
- Centrifugation instrument for cytaphe­resis
  - continuous flow centrifugation, 125–126
  - intermittent flow centrifugation, 123–125
- Cesalpino, Andrea, 2
- Cesium, 281
- Chagas' disease, 164, 428–429
- Channel forming integral protein (CHIP), 192
- Chemical modification of test red cells, 224
- Chemotherapy, extensive, 280
- Chido/Rogers antigens, 193
- Chikungunya virus, 425, 426
- Children and neonates
  - therapeutic apheresis for, 550
  - transfusion therapy in, 331–333, 370, 371
- Chronic benign neutropenia, 479
- Chronic granulomatous disease (CGD), 186
- Chronic inflammatory demyelinating polyradiculoneuropathy, 530
- Chronic lymphocytic leukemia, 546
- Chronic myelogenous leukemia (CML), 9, 132, 505
- Chronic renal failure, 474
- Circulatory effects of transfusion, 59
- Circulatory overload, 401
- Circulatory system (blood), 2
- Citrate toxicity, 59, 399–400
- Citrate–phosphate–dextrose (CPD), 78
- Citrates, 5
- Civilian trauma setting, 312
- Clinical Laboratories Improvement Act (CLIA) of 1998, 25
- CMV negative blood components, 327
- Coagulation factor
  - concentrates, 83–85, 84t
  - inhibitors, 532
  - VIII, 6, 78
- Coagulopathy, 114, 309–310, 381
- Code of Federal Regulations (CFR), 23, 508, 564
- Cohn ADL bowl, 123
- Cohn, Edwin, 8, 123
- Cold agglutinin disease, 532
- Collagen vascular diseases, 534
- Colony forming unit (CFU), 504
- Colton (Co) blood group system, 192, 199
- Community blood centers, activities of, 18–19
- Compatibility testing, 216, 216t, 231–232
- Complement regulatory molecules, 199–200
- Complement dependent cytotoxicity (CDC) technique, 455
- Computer crossmatch, 223
- Computer assisted donor screening, 45
- Confirmatory tests. *See* Laboratory testing of donated blood
- Congenital immune deficiency, 285
- Continuous flow centrifugation, 125–126
- Cooley, Denton, 103
- Coombs and antiglobulin serum, 6–7
- Coombs test, 215, 338
- Cord blood bank development, 502t
- Cord blood stem cells (CBSCs), 497
- Cord blood
  - collection and preservation, 503–504
  - storage conditions for, 504
  - cord blood collection and preservation, 503–504
  - red cell depletion, 504
  - storage conditions, 504
  - suitability determination, 503
  - written consent, 502



- Cord hemoglobin, 329  
 Corrected count increment (CCI), 268, 271, 273  
 Corticosteroids, 57, 61, 132–133  
 Cost effectiveness (autologous blood donation), 109–110  
 Creutzfeldt Jakob disease (CJD), 46, 430–431  
 Critically ill patients, 477–478  
 Crohn's disease, 535  
 Cromer (Cr) system, 193  
 Cromer antigens, 199–200  
 Crossmatch, 220f, 308  
   abbreviated (ABO), 221–222, 321  
   computer, 223  
   full, 221  
   minor, 222–223  
   for platelet transfusion, 272–273, 319  
 Cryoglobulinemia, 532  
 Cryoprecipitate, 78–79, 254–255, 261–262  
   and factor VIII, 8  
 Cryopreservation, 497–498  
 Cryoprotectant, 73–74  
 Crystalloid and colloid solutions, 305t  
 Cytapheresis  
   complications of, 546  
   donation, complications and adverse reactions to, 58t  
   donor programs, 36  
   *See also* Apheresis  
 Cytomegalovirus (CMV), 165–166, 248, 423, 506  
 Cytomegalovirus safe blood components. *See* Blood components, clinical uses of  
 D antigen, structure and composition of, 182–183  
 Decay accelerating factor (DAF), 193  
 Deglycerolizing procedures, 73–74  
 Delayed hemolytic transfusion reaction (DHTR), 382–383, 533  
 Delayed hypersensitivity, 385  
 Dendritic cells, 494t, 505–6  
 Dengue virus, 427  
 Denis, Jean, 2  
 Department of Health and Human Services (HHS), 25  
 Dephenhydramine, 384  
 Dextran sulfate columns, 549  
 Dextran acrylamide particles, 214  
 D galactose *N* acetyl dgalactosamine, 194  
 Diego (Di) system, 191–192, 197  
 Dimethyl sulfoxide (DMSO), 372, 498  
 Diphospho glycerate (DPG), 312–313  
 Direct antiglobulin test (DAT), 153, 154, 212, 215, 215t  
 Direct T cell allorecognition, 456  
 Directed donors, 115–116  
 Disseminated intravascular coagulation (DIC), 259, 310, 341, 381, 545  
 Dithiothreitol (DTT), 224  
 Dombrock (Do) system, 192  
 Dombrock glycoprotein, 200  
 Donated blood, sequence of testing of, 159t  
 Donath–Landsteiner antibody, 190  
 Donor arm preparation for blood collection, 50t  
 Donor blood, tests for, 150t  
 Donor laboratory testing, 503  
 Donor leukocyte infusion (DLI), 505  
 Donor leukocytes, 494t  
 Donor recipient matching, 134  
 Doppler measurement, 233  
 Dose–response effect from platelet transfusion, 268  
 Duffy antigen receptor for chemokines (DARC), 186  
 Duffy system, 186–187  
 Ebola virus, 432  
 Education of donors, 29  
 Elective surgery, 17  
 Electrolyte and acid base imbalance, 400  
 Electrolytes, 314  
 Electromechanical pumps, 369  
 Elliott, John, 7  
 Elution techniques, 226  
 Embolism, 401  
 Employment of blood donors, 30  
 Endoplasmic reticulum (ER), 451  
 Engineered cells, clinical uses of, 492, 493t  
 Enteroviruses, 200

- Enzymatic activity, 200
- Enzymatic cleavage of ABO, 89–90
- Enzyme immunosorbent assay (EIA), 160, 165
- Enzyme linked immunosorbent assay (ELISA), 455
- Enzymes, 213
  - and enhancement media, 224
- Epinephrine, 394
- Epstein Barr virus (EBV), 425, 506–507
  - lymphoproliferative disorders, 506–507
- Errors in transfusion medicine. *See* Blood banking and transfusion medicine
- Erythrocytapheresis, 544
- Erythropoietin (EPO), 103
  - therapy, guidelines for, 476t
  - use of, 109
  - See also* Hematopoietic growth factors
- Evidence based guidelines for transfusion, 101
- Exchange transfusion, 329–31, 330t
  - complications of, 330t
- Extracorporeal photochemotherapy, 546–548
  - See also* photopheresis
- Extravascular hemolysis, 211
- Factor IX, deficiency of, 262
- Factor VII, activated, 312
- Factor VIII, 8
  - deficiency of, 259–260
- Familial hypercholesterolemia, 548–549
- Family history of donation, 33
- Fantus, Bernard, 5
- Fatalities, transfusion related, 361t
- FcRIIIb, 205
- Febrile nonhemolytic transfusion reaction (FNHTR), 384–385, 388, 465
- Federation of Red Cross and Red Crescent Societies, 22
- Fenwal CS 3000, 126
- Fetus, 285
- Fibrin sealant, 255
  - composition of, 256t
  - indications for, 257t
- Fibrinogen, 85, 261
- Filters, 81, 82
- Filtration leukapheresis (FL), 133
- Filtration, 75, 76
- First transfusions, blood (in US), 4
- Fisher–Race system, 182, 183t
- Flaviviridae, 425
- Fluosol, 91
- Food and Drug Administration (FDA), US, 19, 20, 23–24, 219, 508
- Fractionation process (plasma), 19
- Fresenius Kabi
  - Alyx, 127
  - Amicus, 126–127
  - AS, 104 129
- Fresh frozen plasma (FFP), 8, 72, 77–8, 87–88, 252, 253, 253t, 257–258
- Frozen deglycerolized red blood cells, 73–74, 250
- 24 hour Frozen plasma (FP 24), 77, 252, 253
  - thawing, 77–78
- Full crossmatch, 221
- Fulminant hepatitis, 419
- Fya* gene, 186
- Gambro (COBE/Caridian) blood cell separator models, 126
- Gamma irradiation, 282
- G CSF, 61, 137t
- Gel test, 214
- Gender of donors, 28–29
- Gerbich (Ge) system, 193
- GIL antigen, 194
- Global Blood Safety unit, 22
- Glomerulonephritis, rapidly progressive, 531
- Glucose content, 330
- Glucose–citrate mixtures, 7
- Glue, fibrin, 255
- Glycophorins, 193, 197
- Glycosylphosphatidylinositol linkage, 193
- Good manufacturing practices (GMPs), 509–511, 562t, 564
- Goodpasture's syndrome, 530
- Graft survival, alteration of, 396–397

- Graft versus host disease (GVHD),  
249, 280–281, 456  
pathogen inactivation and  
prevention of, 283–284  
prevention of, 283  
transfusion associated, 396t  
bone marrow transplant associated,  
396t
- Graft versus leukemia (GVL) effect,  
456
- Granulocyte colony stimulating factor  
(G-CSF), 132–133, 276  
*See also* Hematopoietic growth  
factors
- Granulocyte concentrate production,  
131–132  
donor–recipient matching, 134  
filtration leukapheresis (FL), 133  
function obtained by leukapheresis,  
133  
granulocyte colony stimulating  
factor (G-CSF), 132–133  
hydroxyethyl starch in  
leukapheresis, 132  
storage for transfusion, 133–134
- Granulocyte, 82, 131–132, 204–206,  
205t  
alloantigens, 205t  
anaplasmosis, 429  
compatibility, 236  
donors, 57  
mobilization in normal donors, 484  
transfusion, 9, 286, 275–276, 329,  
389, 465–466
- Granulocyte specific antigens, 205t
- Guidelines, adherence to, 102
- Guillain Barré syndrome, 522–529
- Guillian–Barré disease, 537
- GVHD, transfusion associated,  
395–396, 396t
- Haemonetics instruments, 128–129, 128f
- Haemonetics system, 125, 126  
Multiple Component System  
(MCS), 129
- Hageman factor, 381
- Haplotypes, HLA, 447–448, 447f
- Haptoglobin, 387
- Harvey, William, 2
- Health professional education  
program, 102
- HemAssist, 91
- Hematologic diseases, 531, 532  
cold agglutinin disease, 532  
cryoglobulinemia, 532  
thrombotic thrombocytopenic  
purpura (TTP), 531–532
- Hematologic malignancies, 284
- Hematoma, 55, 60
- Hematopoietic cell transplantation  
(HCT), 58  
*See also* Transfusion therapy, and  
bone marrow
- Hematopoietic growth factors, 475t  
erythropoietin (EPO)  
acquired immune deficiency  
syndrome (AIDS), 476–477  
anemia of chronic disease,  
475–476  
anemia of prematurity, 477  
autologous blood donors, 477  
bone marrow transplantation,  
477  
chronic renal failure, 474  
complications of, 478  
critically ill patients, 477–478  
description and pharmacology,  
474, 476t  
perioperative situations, 477  
granulocyte colony stimulating  
factor (G-CSF)  
AIDS, 480  
aplastic anemia, 480  
description and pharmacology,  
478, 479t  
granulocyte mobilization in  
normal donors, 484  
neutropenia due to marrow  
suppression, 478–479  
stem cell mobilization in normal  
donors, 480–4, 481f,  
482t, 483f
- second generation  
thrombopoietic growth factors,  
485–6
- thrombopoietin  
description and pharmacology,  
484–5  
due to marrow suppression, 485  
megakaryopoiesis, stimulation of,  
485  
in vitro uses of, 486

- Hematopoietic progenitor cells (HPCs), 37, 492–500, 494t, 494–5t, 499t
- Hematopoietic stem cell preservation
  - cryopreservation, 497–498
  - liquid preservation, 497
- Hematopoietic stem cell products, 371–373, 372t
  - bone marrow, 496–497, 498–9, 499t
  - peripheral blood stem cells, 499
  - umbilical cord blood (UCB), 499–500
- Hematopoietic stem cell transfusion, 262, 263t, 372t
- Hematopoietic stem cells, 496
- Hemochromatosis patients as blood donors, 47
- Hemoglobin testing, 48
- Hemoglobin, 90
  - function, 312–313
- Hemoglobinopathies. *See* Transfusion therapy
- Hemolink, 91
- Hemolysis, 371
  - mechanical, 60
- Hemolytic anemia, 429
- Hemolytic disease of newborn (HDN), 6, 181, 329
  - at risk fetus, monitoring of, 233–234, 234t
  - HDN Rh globulin prevention, 234–235
  - laboratory investigation, 232–233
  - Rh typing, 235
  - prevention, 234–235
  - See also* Laboratory detection of blood groups
- Hemolytic transfusion reactions, 380–382, 380t, 382f, 382t
  - signs and symptoms of, 392t
- Hemophilia
  - A (factor VIII deficiency), 337, 337t
  - B (factor IX deficiency), 337
- Hempure, 91
- Hemorrhage, 4
- Hepatitis A virus (HAV), 166, 415
- Hepatitis B core antibody (anti HBc), 161, 417
- Hepatitis B surface antigen (HBsAg), 160
- Hepatitis B virus (HBV), 415–417, 416f
- Hepatitis B, NAT for, 161
- Hepatitis C antibody (anti HCV), 161
- Hepatitis C virus (HCV), 418
- Hepatitis E virus (HEV), 419
- Hepatitis G, 418–419
- Hepatitis tests. *See* Laboratory testing of donated blood
- Hepatitis, surrogate testing for, 161–162
- Hereditary hemochromatosis (HHC), 47, 467
- Heterodimers, 451
- Heterophil positive mononucleosis, 425
- Histamine, 385
- History, 1–10
  - ancient times, 1
  - anticoagulation, 4–5
  - apheresis, 9
  - blood banking/banks, 5
  - blood groups, discovery of, 4
  - cadaver blood, 5–6
  - coombs and antiglobulin serum, 6–7
  - cryoprecipitate and factor VIII, 8
  - first transfusions (in US), 4
  - granulocyte transfusions, 9
  - leukocyte antigens and antibodies, 8–9
  - plasma, 7
  - plastic bags and blood components, 7–8
  - platelet collection/storage/transfusion, 9
  - red cell preservation, 8
  - Rh blood group system, 6
  - Rh immunization, prevention of, 6
  - time period
    - 1500–1700, 1–3
    - 1800s, 3
    - World War II, 7
- HIV. *See* Human immunodeficiency virus (HIV)
- HLA. *See* Human leukocyte antigens (HLA)
- Hospital blood bank operations, 571–572, 571t
- Hospital Laboratory Accreditation Program (HLAP), 25–26

- Human herpesvirus 6 (HHV 6)/  
Human herpesvirus 8  
(HHV 8), 426
- Human immunodeficiency virus (HIV)
  - antibody tests, 421
  - antigen testing, 159–160, 421
  - infection and AIDS (*See under*  
Transfusion transmitted  
diseases)
  - laboratory screening tests, 420
  - testing, 158
- Human leukocyte antigen (HLA)
  - matching, 286–287
  - for platelet transfusion, 271–272,  
272f
- Human leukocyte antigen (HLA)
  - system in transfusion medicine
    - clinical HLA testing for  
transplantation
      - cellular assays, 453
      - HLA antibody screening, 455
      - lymphocyte crossmatch, 455
      - molecular typing of HLA alleles,  
453–455, 453t
      - serologic typing of HLA antigens,  
452–453
    - genomic organization of  
humanMHC, 446–447
    - HLA haplotypes, 447–448, 447f
    - human minor histocompatibility  
antigens, 456
    - immunologic role of (peptide  
presentation), 450–452
    - structure and polymorphism of,  
448–450, 449f
    - tissue expression of, 448
  - in transfusion therapy
    - Febrile nonhemolytic transfusion  
reaction (FNHTR), 465
    - granulocyte transfusion, 465–466
    - HLA alloimmunization, 461
    - HLA disease association, 467
    - neonatal alloimmune  
thrombocytopenia (NAIT),  
466–467
    - parentage HLA testing, 468
    - refractoriness to platelet  
transfusion, 462–463
    - transfusion associated graft  
versus host disease (TA  
GVHD), 463–465
    - transfusion related acute lung  
injury (TRALI), 466
    - in transplantation, 456–457
      - allogeneic hematopoietic stem  
cell transplantation,  
459–460
      - solid organ transplantation,  
457–459
- Human leukocyte antigen (HLA), 8,  
18, 166
- Human minor histocompatibility  
antigens, 456
- Human platelet alloantigens,  
202–203t
- Human T lymphotropic virus  
(HTLV), 160, 423–424
- Human transfusion, 3
- Hydroxyethyl starch (HES), 57, 61, 82,  
132, 304, 539
  - in leukapheresis, 132
- Hyperacute rejection, 457, 458
- Hyperhemolysis, 335
- Hypersensitivity, passive transfer of,  
401
- Hypertension, 61
- Hyperviscosity syndrome, 532
- Hypocalcemia, 313
- Hypofibrinogenemia, 261
- Hypo proliferative thrombocytopenia,  
263
- Hypotension, 394
- Hypotensive reactions, 388
- Hypothermia, 313, 399
- Identity theory, 30
- Idiopathic thrombocytopenicpurpura,  
AIDs related, 535
- IgA deficiency.
  - screening donors for, 167
  - See also* Transfusion therapy
- IgM antibodies, 226
- Ii blood group antigens, 194–195
- Immune cytopenias, 322
- Immune serum globulin, 85–87
- Immune system, 252
- Immunization, 181
  - after blood transfusion, 394t
  - to blood group antigens, 394, 394t
- Immunotherapy, 506, 507
- In vivo red cell compatibility testing,  
231–232

- Incentives, role of, 34
- Incompatible crossmatch, patient with, 230–232
- Indian (In) system, 193–194
- Infusion pumps, 369
- Infusion solutions, 365
- Inspection and Accreditation (I&A) program, 25
- Integral plastic bag system, 71f
- Integrated model (blood donation), 30–31
- Intensive care units (ICU), 477
- Intermittent flow centrifugation, 123–125
- Internal quality audits, 568
- International normalized ratio (INR), 253
- International Organization for Standardization (ISO), 563t, 564
- International Society for Blood Transfusion (ISBT), 22–3
- Intracellular adhesion molecule (ICAM), 191
- Intraoperative blood salvage. *See* Autologous blood donation and transfusion
- Intravenous immune globulin (IVIG), 41, 86–87, 342–344, 466, 529, 533, 535
- Intravenous infusion sets, 363
- Investigational device exemptions (IDEs), 509
- Investigational new drug (IND), 493t
- Iron overload, 401
- Irradiated blood components, 328
  - acquired immune deficiency syndrome, 285–286
  - allogeneic bone marrow transplantation, 284
  - aplastic anemia, 285
  - autologous bone marrow transplantation, 284
  - congenital immune deficiency, 285
  - fetus, 285
  - granulocyte transfusions, 286
  - hematologic malignancies, 284
  - HLA matching, 286–287
  - neonates, 285
  - noncellular blood components, 286
  - solid tumors, 285
  - See also* Blood components, clinical uses of
- Irradiation
  - of blood components, 82, 281–282
  - quality control of, 283
  - storage, 282–283
  - See also* Plasma derivatives
- John Milton Hagen (JMH), 194
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 574
- Kell glycoprotein, 200
- Kell system, 185–186
- Kidd system, 187
- Kidney transplantation, 277–278, 322–323
- Knops (Kn) system, 193
- Labeling, 49
  - errors, 361
  - systems, 223–224
- Laboratory detection of blood groups
  - direct antiglobulin test (DAT), 215, 215t
  - hemolytic disease of newborn (HDN), 232–235
    - at risk fetus, monitoring of, 233–234, 234t
    - HDN Rh globulin prevention, 234–235
    - laboratory investigation, 232–233
    - Rh typing, 235
  - immunologic mechanisms of red cell destruction, 210–211
  - incompatible crossmatch, patient with, 230–232
    - in vivo red cell compatibility testing, 231–232
    - phagocytosis related assays, 232
  - red cell antibody antigen reaction
    - agglutination, 211
    - antigen–antibody reaction enhancement, 212–213
    - detection tests, 214–215
  - red cell antibody identification, 224–226, 225f
    - absorption, 226

- chemical modification of test red cells, 224
- elution, 226
- enzymes and enhancement media, 224
- neutralizing/inhibitor substances, 226
- sulphydryl reagents, 226
- red cell availability for transfusion
  - blood availability, 226–228, 227t, 230
  - crossmatch, emergency, 229
  - surgical blood ordering (standard/maximum), 228
  - type and screen, 228–229
  - uncrossmatched red cells, 229–230
- red cell compatibility testing,
  - 216–217, 216t, 217t
  - ABO and Rh typing, 218–219, 219t
  - crossmatch, 221–223

- Leukocyte reduced red blood cells, 75–77, 76t
  - definition of component, 75
  - leukocyte depletion filters, 76–77
  - leukodepletion, history of, 75–76, 76t
- Leukocytes, 8–9
  - antibodies, 8–9, 386
  - antigens, 8–9
  - in blood components, adverse effects of, 76t, 378t
- Leukodepletion,
- Leukopenia, 341
- Lewis system, 190–191
- Libavius, Andreas, 1–2
- Licensure, 24, 25, 68t
- Lipids, 173
- Liquid preservation, 497
- lookback, objectives of, 162–163
- Lower, Richard, 2
- Low ionic strength solution (LISS), 213
- Lupus anticoagulant, 341
- Lutheran antigen, 188, 197
- Lutheran system, 188
- LW system, 191
- Lyme disease, 429
- Lymphocytapheresis, 134–135
- Lymphocyte crossmatch, 455
- Lymphocyte depletion, 60–61
- Lymphocytotoxicity, 134
- Lymphoplasmapheresis, 534
- Lymphoproliferative disease, 506
- Major histocompatibility complex (MHC), 505
- Malaria, 428
- Massive transfusions, 308–309, 309t
  - coagulopathy in, 309–310
- Mauroy, Antoine, 2–3
- McLeod phenotype, 186
- Mechanical barrier system, 362
- Mechanical hemolysis, 60
- Medical Event Reporting System for Transfusion Medicine (MERS TM), 570
- Medical history of whole blood donors, 43–47, 44–45t
- Medications, 365
- Medico Chirurgical Society of London, 3
- Megakaryocyte growth and development factor (MGDF), 485
- Megakaryopoiesis, stimulation of, 485
- Mendelian inheritance of HLA haplotypes, 448f
- Mesenchymal stem cells (MSCs), 507
- Microaggregates, 313–314
- Microbial receptor, 200
- Microchimerism, 399
- Microhematocrit, 48
- Middle cerebral artery (MCA), 233
- Military trauma center, 311
- Minimal donor exposure programs, 116–117
- Minor crossmatch, 222–223
- Minor histocompatibility antigen, 456
- Mixed lymphocyte culture (MLC), 274
- MNSs system, 188–189
- Molecular typing of HLA alleles, 453–455, 453t
- Molecules, function of. *See* Blood groups
- Monoclonal gamopathies, 530
- Monocyte monolayer assay (MMA), 232
- Mononuclear cell apheresis, complications in, 62
- Mononuclear cell collection, lymphocytapheresis for, 134–135
- Mortality risk scores, 458
- Mortality, overall, 398–399
- Multiple coagulation factors, deficiency of, 255–259
  - disseminated intravascular coagulation, 259
  - massive transfusion, 258–159
  - prothrombin complex deficiency, 257–258, 258f
- Multiple Component System (MCS), 129
- Multiple myeloma, 531
- Multiple sclerosis, 529
- Murine myeloproliferative leukemia virus, 484
- Myasthenia gravis, 529
- Mycoplasma pneumoniae* infection, 195
- Myelogenous leukemias, 545



- Myeloid recombinant growth factor therapy, 478, 479t
- Myocardial repair, 507
- Nageotte chamber, 77
- NAT. *See* Nucleic acid amplification testing (NAT)
- National Academy of Sciences, 281, 433
- National Blood Foundation, 21
- National Cancer Institute (NCI), 9, 125
- National Institutes of Health (NIH), 9, 244, 417
- National Marrow Donor Program (NMDP), 36, 459–460, 497
- Natural killer (NK) cells, 451–2, 505
- NCI IBM Blood Cell Separator, 125
- Neonatal alloimmune neutropenia, 344–345
- Neonatal alloimmune thrombocytopenia (NAIT), 343–344, 466–467
- Neonates, 277, 285  
transfusion for, 325–331, 370–371
- Nerve injuries, 54
- Neurologic diseases, 522
- Neuromyelitis optica, 530
- Neutropenia  
chronic benign, 479  
due to marrow suppression, 478–479  
neonatal alloimmune, 344–345
- Neutrophils, 204–205, 387
- Nitric oxide, 243
- Noncellular blood components, 286
- Nongovernmental blood bank organizations. *See* Blood supply
- Nonhospital setting, transfusion in, 373
- Nonimmunologic complications of blood transfusion. *See* Transfusion, complications of
- Nonimmunologic hemolysis, 384
- Noninfectious serious hazards of transfusion (NISHOT), 377
- Nucleic acid amplification testing (NAT), 160, 163–164, 417, 421  
for hepatitis B, 161
- Nursing care of patients, 369–370
- Octaplas, 87, 88t
- OK system, 194
- Opponent process theory, 30
- Optional tests for donor blood. *See* Laboratory testing of donated blood
- Organ preservation, 458
- Organizational influences on blood donation, 33–34
- Osmotic hemolysis, 73
- Outpatient transfusions, 19
- Oxalic acid, 5
- P system, 189–190
- Packed red blood cells (PRBCs), 72, 311
- Panel reactive antibody (PRA), 455
- Parasitic diseases, 427–429  
Chagas' disease, 428–9  
malaria, 428
- Parentage HLA testing, 468
- Paroxysmal cold hemoglobinuria, 190
- Paroxysmal nocturnal hemoglobinuria (PNH), 200, 324–325
- Parvovirus, 424–425  
and hepatitis A virus, 166
- Passenger lymphocyte related hemolysis, 383–4
- Passenger lymphocytes, 324
- Passive transfer of hypersensitivity, 401
- Pasteurization, 83
- Pathogen inactivation techniques, 87–89, 274
- Pathogen inactivated blood components. *See* Blood components
- Patient blood management (PBM), 100–101, 101t  
acute normovolemic hemodilution, 110–112, 112t  
allogeneic transfusion, 103, 106  
blood use monitoring, 102  
directed donor blood, 115–116  
donors, 477  
evidence based guidelines for transfusion, 101  
guidelines, adherence to, 102  
hemostatic agents minimizing transfusion, 115  
intraoperative blood salvage

- blood salvage, development of, 112–113
- devices used for, 113–114, 113t
- limiting blood loss for laboratory testing, 115
- minimal donor exposure programs, 116–117
- ordering practices, 573
- patient specific donation, 116
- physician and health professional education program, 102
- postoperative blood salvage, 114–115
- preoperative anemia detection and management, 102–3
- preoperative autologous donor blood, 103–106, 104t
  - adverse reactions to, 107–108
  - blood donation by infectious patient, 108–109
  - collection processing, 107
  - complications of transfusion, 110, 110t
  - cost effectiveness, 109–10
  - erythropoietin, use of, 109
  - indications for transfusion, 109
  - laboratory testing, 108
  - medical requirements, 106–107, 106t
  - storage of blood, 107
- Patient specific blood donation, 116
- PBSC. *See* Peripheral blood stem cells (PBSC)
- Pediatric patients, transfusion therapy in, 331–333
- Pegelius, Magnus, 1
- Pemphigus, 535
- Peptide presentation, 450–452
- Percutaneous mechanical thrombectomy, 384
- Percutaneous umbilical cord blood sampling (PUBS), 233
- Perfluorocarbon, 90, 91
- Peripheral blood lymphocytes (PBLs), 451–2
- Peripheral blood mononuclear cells, 505
- Peripheral blood platelet counts, 483f
- Peripheral blood stem cells (PBSC), 62, 497, 499
  - collection on normal donors, effects, 137
  - collection procedures, 136–137
  - concentrates, characteristics of, 137–138, 137t, 138t
  - donor selection, 140
  - plasmapheresis and source plasma, 140–141
  - quality control of, 138–139, 138t, 139f
  - quantity of cells in, 138t
  - storage of, 139–140
- Pertussis, malignant, 535
- Phagocytosis, 133
  - related assays, 232
- Philosophical Transactions of Royal Society, 2
- Phlebotomists, 50t, 51
- Phosphate dextrose (CPD), 503
- Phosphatidylinositol, 173, 178f
- Phosphatidyl inositol glycan (PIG), 205
- Photometers, 154
- Photopheresis, 546–548, 547t
- Phylogenetic analysis, 179
- Physical examination of blood donor, 47–49
- Physician education program, 102
- Physiology in red cell transfusion decisions, 242–244, 243t
- Plasma Protein Therapeutics Association (PPTA), 22
- Plasma, 78, 252
  - and blood program, 7
  - collection activity, 20
  - collection system (*See* Blood supply)
  - definitions of, 19
  - derivatives (*See also* Blood components)
    - coagulation factor concentrates, 83–85, 84t
    - fibrinogen, 85
    - immune serum globulin, 85–87
  - exchange (*See* Therapeutic apheresis)
  - histamine, 385
  - protein depletion, 61
  - production for transfusion, 18
- Plasmapheresis, 19
  - complications, 61
  - donors, 57–58
  - and source plasma, 140–141
- Plasmodium falciparum*, 193, 428

- Plasmodium knowlesi*, 187  
*Plasmodium vivax*, 187  
 Plastic bags, 9  
   and blood components, 7–8  
 Plasticizers, 314  
 Platelet collection/storage/transfusion, 9  
 Platelet transfusion, 262–274, 263t  
   active bleeding, treatment, 265–268, 266f, 267f  
   outcome, 268–71  
     ABO and Rh in, 268–270  
     patient factors, 270, 271t  
     platelet concentrate factors, 271  
   prevention of bleeding  
     (prophylaxis), 263–265, 264f  
     indications for transfusion, 264  
     platelet dose, 264–265  
   prophylaxis for invasive procedures, 268  
 Platelet transfusion refractoriness, 270  
   management strategies, 271–274  
   alloimmunization prevention, 274  
   crossmatching, 272–273, 273t  
   HLA matching, 271–272, 272f  
   other approaches, 273  
 platelet concentration volume,  
   reduction of, 274  
   outcome, 270  
 Plateletpheresis, 129–130, 131, 262  
 Platelet rich plasma (PRP) method, 80, 80f  
 Platelets, 88–89, 200–204, 202–203t, 204t  
   additive solutions, 79t  
   apheresis, 262  
   compatibility, 235–236  
   concentrate, 79–82, 79t, 80f, 274  
   crossmatching, 272, 273  
   depletion, 57  
   depletion/damage, 60  
   function and storage of, 130  
   production, 17  
   refractoriness prevention, 274  
   refractory patient, 273, 273t  
   transfusion, 9, 262–274, 328, 341, 388  
 Pluripotent hematopoietic stem cells, 499  
 Poliovirus, 200  
 Polybrene, 213  
 Polyethylene glycol (PEG), 213  
 Polyheme, 91  
 Polymerase chain reaction (PCR), 454  
 Polypeptides, 177  
 Pool, Judith, 8  
 Positive direct antiglobulin tests, 154–155  
 Postdonation care, 52  
 Postoperative blood salvage, 114–115  
 Postpartum hemorrhage, 3  
 Postperfusion syndrome, 425  
 Posttransfusion purpura (PTP), 533  
 Pregnancy, 334  
 Pregnant women, 277  
   transfusion therapy, 340  
 Preoperative autologous donor blood, 103–106, 104t  
   adverse reactions to, 107–108  
   blood donation by infectious patient, 108–109  
   cardiovascular conditions, 106, 106t  
   collection processing, 107  
   complications of transfusion, 110, 110t  
   cost effectiveness, 109–10  
   erythropoietin, use of, 109  
   indications for transfusion, 109  
   laboratory testing, 108  
   medical requirements, 106–107, 106t  
   storage of blood, 107  
 Preservative solutions, anticoagulant, 8  
 Prestorage leukodepletion, 76  
 Pretransfusion testing, 326  
 Process analysis and management (PAM), 561  
 Procoagulant activity, 381  
 Progenitor cells, 82–83, 494t  
 Prophylaxis,  
   invasive procedures, 268  
   platelet transfusion, 268  
 Prothrombin complex deficiency, 257–258, 258f  
*Pseudomonas*, 389  
 Psoralen, 88  
 Psychosocial theories (to blood donor motivation), 30  
 Push pull technique, 334

- Quality assurance
  - in blood supply system, 564–569
  - leadership, 565
  - in patient therapy (*See* Blood banking and transfusion medicine)
  - systems, 560–564, 561t, 562t, 563t, 564t
  - in transfusion service, 570–574
- Quality systems in blood supply. *See* Blood banking and transfusion medicine
- Quality
  - hierarchy, 564t
  - principles (by AABB), 562t
  - in transfusion therapy, 570–571
- Quinton–Mahurkar catheters, 536
  
- Race/ethnicity of donors, 29
- Radiation dose, 281–282
- Radioimmoblot assay (RIBA), 158
- RAPH system, 194
- Rare blood types, 197t, 345–346
- RBC membrane proteins, 178f
- Reagent red cells used for antibody identification, 225f
- Receptors and adhesion molecules, 198–199
- Recurrent spontaneous abortions, 507
- Red blood cell components, use of, 246–250
- Red blood cell transfusion, effects of, 251–252
  - circulation, 251
  - hemoglobin concentration, 251
  - immune system, 252
  - red cell production, 252
  - transfused red blood cells, survival of, 252
  - see also* blood components, clinical uses of
- Red blood cells, 72–73, 72t
  - antibody detection, 153–154
  - component, description of, 73–74
  - frozen/deglycerolized, 73–75
  - leukocyte reduced, 75–77, 76t (*See* Leukocyte reduced red blood cells)
  - storage conditions/duration, 72t, 73
  - transfusions, 325–326
  - transfusion trigger, 244–245
  - washed red cells, 75
- Red cell antibody characterizing, 196t
  - identification *See* Laboratory detection of blood groups)
- Red cell antibody antigen reaction, detection
  - affinity column, 215
  - gel test, 214
  - slide/tiletest, 214
  - solid phase tests, 214
  - tube tests, 214
  - See also* Laboratory detection of blood groups
- Red cell antigen, 166
  - alteration, 198t
  - antibodies to, 195–196, 196t
- Red cell aplasia, 533
- Red cell availability for transfusion. *See* Laboratory detection of blood groups
- Red cell blood groups. *See* Blood groups testing; Laboratory testing of donated blood
- Red cells, 89
  - alloantibodies, 336
  - in AS 1 (Adsol), 70t
  - clinical uses of, 246
  - see also* blood components, clinical uses of
  - collection, 130–131, 131t
  - compatibility testing *See* Laboratory detection of blood groups
  - depletion, 504, 544
  - destruction, immunologic mechanisms of, 210–211
  - exchange, 544
  - function, 198, 199t
  - hemolysis, causes of, 380t
  - preservation, 8
  - products used, 326–327
  - structure, 197–198, 198t
  - universal, 89–90
  - washed, 75, 249–50
- Refractoriness to platelet transfusion, 462–463
  - management strategies, 271–274
    - alloimmunization prevention, 274
    - crossmatching, 272–273, 273t
    - HLA matching, 271–272, 272f
    - other approaches, 273
  - outcome, 270

- Registration of blood donors, 42–43
- Renal diseases  
 glomerulonephritis, rapidly progressive, 531  
 Goodpasture's syndrome, 530  
 multiple myeloma, 531
- Repeat identification of red cell antibodies, 217t
- Respiratory problems, 394
- Restriction fragment length polymorphism (RFLP), 453
- Rh  
 antigen, 89–90  
 blood group system, 6  
 immunization, prevention of, 6  
 system *See* Blood groups  
 type, 151–152, 235–236  
*RHCE*, 182  
 Rheumatoid arthritis, 534  
 Rh immune globulin (RhIG), 235  
 Rh incompatible transplants, 319–322, 320f, 320t  
 Rh mismatched transplants, 321  
 Rh null individuals, 184  
 Riboflavin, 87–88  
 Robertson, Oswald, 5  
 Rocky mountain spotted fever (RMSF), 430  
 Rogers (Rg) and chido (Ch) system, 193  
 Roller pumps, 369  
 Rous, Peyton, 69
- Safe blood, strategies of, 42t
- Scianna (Sc) system, 192
- Scleroderma, 534
- Screening test, 219–220, 221t
- Sedimentation, 72
- Seizures, 54
- Semiautomated apheresis methods, 122
- SEN virus, 419
- Sepsis, 390t, 535  
 neonatal, 329
- Sequence based typing, 454
- Sequence specific oligonucleotide probe (SSOP) methods, 454
- Sera testing, 344
- Serial donations, complications of  
 leukapheresis donors, 57  
 plasmapheresis donors, 57–58  
 platelet depletion, 57
- Serologic typing of HLA antigens, 452–453
- Serum chemistries, 482t
- Severe combined immune deficiency (congenital), 279–280
- Sickle cell disease (SCD), 329, 333–336, 333t  
 components, 336  
 red cell antibodies, 334–335  
 transfusion, clinical indications for, 333–334, 333t  
 transfusion reactions, 335
- Simian foamy virus (SFV), 427
- Single coagulation factors, deficiency of, 259–262  
 factor IX, deficiency of, 260–261  
 factor VIII, deficiency of, 262  
 fibrinogen, 261  
 hypofibrinogenemia, 261  
 von Willebrand's disease, 261–262
- Single donor platelet concentrate production, 129–130
- Single use reservoirs, 113
- Slide/tile typing, 214
- Social influences on blood donation, 32–33
- Socioeconomic characteristics, 29
- Solid organ transplantation, 322–324, 457–459, 533–534
- Solid phase tests, 214
- Solid tumors, 285
- Solvent detergent plasma, 87, 88t, 254
- Solvent detergent (SD) process, 84, 254
- Source plasma, 19, 140–141
- Southern blotting analysis, 453
- Spontaneous bleeding, 267
- Standard operating procedures (SOPs), 561
- Staphylococcal protein A (SPA) columns, 549–550
- Staphylococcus epidermidis*, 389
- Stem cell  
 mobilization in normal donors, 480–484, 481f, 482t, 483f  
 sources of, 492–3, 494t  
 transplantation, transfusion in, 461  
*See also* Cellular engineering, hematopoietic stem cells, and progenitor cells

- Sterile connector devices, 116–117
- Stored red blood cells, clinical effects of, 246
- Sulfhydryl reagents, 226
- Surgical blood ordering (standard/maximum), 228
- Surrogate testing, 417–418
  - for hepatitis, 161–162
- Syphilis, 412–413
  - testing of donated blood, 163
- Systemic lupus erythematosus (SLE), 534
  
- T activation, 328
- T lymphocytes, 500
- Taq polymerase, 454
- TEG/ROTEM, 310, 310f, 310t
- Terumo Trima Accel™, 127–128
- Thalassemia, 335
- Thawing, 77–78, 498
- Theory of planned behavior (TPB) on blood donation, 31
- Theory of reasoned action, 30
- Therapeutic apheresis
  - in children, 550
  - photopheresis, 546–548, 547t
  - plasma exchange therapy
    - apheresis procedure, 543–544
    - biochemical changes, 539–540, 540f, 541f
    - complications of, 541–544, 542t
    - red cell depletion, 544
    - replacement solutions, 538–539, 538t, 543
    - techniques of, 536–537, 537f
    - vascular access for plasma exchange, 535–536, 542–543
  - plasma exchange therapy, clinical uses of, 521–522, 522t, 523t–528t
  - alloimmune platelet refractoriness, 533
  - amyotrophic lateral sclerosis (ALS), 530
  - autoimmune hemolytic anemia, 533
  - autoimmune thrombocytopenia, 533
  - catastrophic antiphospholipid syndrome, 532
  - chronic inflammatory demyelinating polyradiculoneuropathy, 530
  - coagulation factor inhibitors, 532
  - collagen vascular diseases, 534
  - delayed hemolytic transfusion reaction, 533
  - Guillain Barre syndrome, 522–529
  - hematologic diseases, 531–532
  - hyperviscosity syndrome, 532
  - idiopathic thrombocytopenic purpura, AIDs related, 535
  - infectious and inflammatory diseases, 535
  - Lambert–Eaton syndrome, 530
  - monoclonal gamopathies, 530
  - multiple sclerosis, 529
  - myasthenia gravis, 529
  - neurologic diseases, 522
  - neuromyelitis optica, 530
  - pemphigus, 535
  - posttransfusion purpura (PTP), 533
  - red cell aplasia, 533
  - renal diseases, 530–531
  - rheumatoid arthritis, 534
  - scleroderma, 534
  - solid organ transplantation, 533–534
  - systemic lupus erythematosus (SLE), 534
  - Wilson's disease, 535
- red cell exchange/erythrocytapheresis, 544
- selective adsorption columns, use of
  - dextran sulfate columns, 549
  - familial hypercholesterolemia, 548–549
  - staphylococcal protein A (SPA) columns, 549–550
- therapeutic cytapheresis, 544–546
  - complications of, 546
  - myelogenous leukemias, 545–546
  - thrombocytosis, 546
- Therapeutic bleeding, 55
- Therapeutic cytapheresis, 544–546
  - complications of, 546
  - myelogenous leukemias, 545–546
  - thrombocytosis, 546

- Therapeutic plasma exchange (TPE),
  - use of, 522t
  - See also Therapeutic apheresis
- Thrombocytopenia, 9, 262, 309, 341
  - neonatal alloimmune, 343–344
- Thrombocytosis, 546
- Thromboelastogram measures, 315
- Thrombopoietic growth factors,
  - second generation, 485–6
- Thrombopoietin (TPO), 484–5
  - See also Hematopoietic growth factors
- Thrombosis, 55
- Thrombotic thrombocytopenic purpura (TTP), 531–532
- Tick borne diseases, 429–430
  - babesiosis, 429
  - granulocyte anaplasmosis, 429
  - lyme disease, 429
  - rocky mountain spotted fever (RMSF), 430
- Toscana virus, 426
- Total process control, 561
- Toxoplasmosis, 431
- Transcription errors, 158
- Transfusion committee, 574
- Transfusion medicine
  - errors in, 569–570, 572
  - quality program, 570t
- Transfusion Safety Officer, 100, 102
- Transfusion service record review, 217–218
- Transfusion therapy
  - acute blood loss
    - acid base balance, 313
    - activated factor VII, 312
    - blood bank procedures, 306–307
    - blood samples for laboratory tests, 314
    - blood types, changing, 307–308, 307t
    - coagulopathy, 309–310
    - electrolytes, 314
    - hemoglobin function, 312–313
    - hypocalcemia, 313
    - hypothermia, 313
    - massive transfusion, 308–309, 309t
    - microaggregates, 313–314
    - physiology and therapy, 304–306, 305t
    - plasticizers, 314
    - TEG/ROTEM, 310, 310f, 310t
    - trauma, 311–12
- AIDS
  - anemia, 340–1
  - disseminated intravascular coagulopathy, 341
  - leukopenia, 341
  - lupus anticoagulant, 341
  - thrombocytopenia, 341
- autoimmune hemolytic anemia (AIHA), 339t
  - decision to transfusion, 338–340
- autoimmune neutropenia (AIN), 345
- autoimmune thrombocytopenia, 342–343
- cardiovascular surgery, 314–316
  - stored red blood cells in, 316
- hematopoietic cell transplantation (HCT), 316–318, 317t
  - ABO and Rh incompatible transplants, 319–322, 320f, 320t
  - immune cytopenias, 322
  - posttransplantation, 318–319
  - posttransplant chimeric states, 322
  - pretransplant, 318
- in hemoglobinopathies
  - sickle cell disease, 333–336, 333t
  - thalassemia, 335
- hemophilia, 337, 337t
- with IgA deficiency, 341–342
- neonatal alloimmune neutropenia, 344–345
- neonatal alloimmune
  - thrombocytopenia, 343–344
- neonates, 325–331
  - administration devices, 327
  - CMV negative blood components, 327
  - exchange transfusion, 329–331, 331t
  - granulocyte transfusions, 329
  - irradiated blood components, 328
  - platelet transfusions, 328
  - pretransfusion testing, 326
  - red blood cell transfusions, 325–326
  - red cell products used, 326–327
  - T activation, 328

- paroxysmal nocturnal
  - hemoglobinuria (PNH)
  - patients, 324–326
- pediatric patients transfusion
  - techniques, 331–333
- pregnant women, 340
- rare blood types, 345–346
- solid organ transplantation,
  - 322–324, 533–534
  - blood group antibodies, 324
  - vonWillebrand's disease, 337–338
- Transfusion
  - on AIDS, effect of, 422
  - committee, 574
  - massive, 258–259, 308–309, 309t
  - coagulopathy in, 309–310
- Transfusion, complications of,
  - 377–379, 378t, 379t, 380t
  - acute lung injury (ALI), 385–387, 386t
  - allergic reactions, 385
  - anaphylactic reactions, 387
  - bacterial contamination
    - transfusion transmitted, 389–391, 390t
  - delayed hemolytic transfusion
    - reaction (DHTR), 382–383
  - febrile nonhemolytic transfusion
    - (FNHT) reactions, 384–385
  - granulocyte transfusions, 388–389
  - hypotensive reactions, 388
  - in immune modulation
    - GVHD, transfusion associated, 395–396, 396t
    - immunization to blood group antigens, 394, 394t
    - transfusion related, 396
  - immunological complications of
    - transfusion
      - graft survival, alteration of, 396–397
      - long term mortality, 398–399
      - microchimerism, 399
      - susceptibility to infection, increased, 398
      - susceptibility to recurrence of malignancy, increased, 397–398
  - immunologic complications of
    - hemolytic transfusion
      - reactions, 380–384, 380t, 382f, 382t
      - management of, 392, 393t
    - nonimmunologic complications of
      - bleeding tendency, 400
      - circulatory overload, 401
      - citrate toxicity, 399–400
      - electrolyte and acid–base imbalance, 400
      - embolism, 401
      - hypothermia, 399
      - iron overload, 401
    - nonimmunologic hemolysis, 384
    - passenger lymphocyte related
      - hemolysis, 383–4
    - platelet transfusions, 388
    - signs and symptoms of, 391–392, 392t, 393t
    - treatment of, 394
  - passive transfer of hypersensitivity, 401
    - See also* Transfusion related immunomodulation (TRIM)
- Transfusion associated graft *versus* host disease (TA GVHD), 281, 463–465
- Transfusion associated
  - microchimerism (TAMC), 399
- Transfusion related acute lung injury (TRALI), 166, 377, 385, 386, 386t, 461, 466
- Transfusion related
  - immunomodulation (TRIM), 249, 396
- Transfusion transmitted diseases,
  - 413t, 414t, 422t
  - bacterial, 427
  - parasitic and tick borne, 427–30
  - viruses, 422–427
  - estimates of (in US), 414t
  - screening, 156t
  - bacterial infections
  - leishmaniasis, 430
  - parasitic diseases, 428–429
  - tick borne diseases, 429–430
  - chikungunya virus, 425, 426
  - current issues with
    - bovine spongiform encephalopathy, 430–431
    - variant Creutzfeldt–Jakob disease (vCJD), 83, 430–431
  - cytomegalovirus (CMV), 423
  - dengue virus, 427



- Transfusion transmitted diseases  
(*cont'd*)
- Epstein-Barr virus (EBV), 425
  - hepatitis, 413–15
    - hepatitis A virus (HAV), 415
    - hepatitis B virus (HBV), 415–417, 416f
    - hepatitis C, 418
    - hepatitis E virus (HEV), 419
    - hepatitis G, 418–419
    - non A, non B hepatitis and surrogate testing, 417–418
    - SEN virus, 419
    - surrogate testing, 417–418
    - TT virus (TTV), 419
  - HIV infection and AIDS, 410, 420f
    - anti HIV negative blood (window phase), transfusion of, 421
    - anti HIV 1 positive blood, transfusion of, 422
    - HIV 1 antibody tests, 421
    - HIV antigen testing, 421
    - HIV laboratory screening tests, 420
    - nucleic acid amplification testing, 421
    - transfusion on AIDS, effect of, 422
  - Human herpesvirus 6 (HHV 6)/ Human herpesvirus 8 (HHV 8), 426
  - human T lymphotropic virus I and II, 423–424
  - influenza, 431
  - parvovirus, 424–425
  - screening tests (new), 432–433, 432t
  - simian foamy virus, 427
  - syphilis, 412–413
  - toscana virus, 426
  - West Nile virus (WNV), 425
  - xenotropic murine leukemia virus related virus (XMRV), 431
  - Zika virus, 425–426
- Transmissible diseases testing, 14  
*See also* Laboratory testing of donated blood
- Transport protein, 199
- TRAP study, 274
- T regulatory cells, 504–505
- Treponema pallidum*, 163, 413
- Tri *n* butyl phosphate (TNBP), 84
- Triton X100, 87
- Trypanosoma cruzi*, 164, 428–429  
*See also* trypanosomiasis
- TT virus (TTV), 419
- Tube tests, 214
- Tullis, James, 123
- Tumor cell purging, 500
- Tumor vaccines (translational development), 495t
- Ultraviolet B (UVB) irradiation, 463, 464
- Ultraviolet irradiated platelets, 274
- Umbilical cord blood (UCB), 497, 499–500
  - banking *See* Cellular engineering and cord blood
- Uncrossmatched red cells, 229–230
- United Network for Organ Sharing (UNOS), 457
- United States Federal Regulation of blood supply system, 23–25
- United States
  - blood supply, 15–16
- Universal red cells, 89
  - enzymatic cleavage of ABO and Rh antigen, 89–90
- Urticaria, autoimmune, 535
- Variant Creutzfeldt–Jakob disease (vCJD), 83, 430–431
- Vascular access for plasma exchange, 535–536
- Vasodilatation, 544
- Vasovagal syndrome, 53
- Vein selection, 50
- Venipuncture, 51, 364
  - site preparation, 50, 50t
- Venous access, 364
- Viral testing, 158
- Viremia, 415, 431
- Virtual crossmatching, 455
- Voluntary accreditation of blood banks, 25
- Volunteerism, 33
- VonWillebrand's disease, 79, 261–262, 337–338
- Vox Sanguinis* (journal on blood transfusion), 23

- Walter, Carl, 7
- Washed red cells, 75, 249–50
- West Nile virus (WNV), 425
  - infection, 163–164
- Western blot, 159
- Whole blood donors
  - medical assessment of *See* Blood donor medical assessment
  - donor medical assessment
  - motivation of *See* Blood donors, recruitment of
  - recruitment strategies of, 34–35
- Whole blood, 247
  - collection of *See* Blood donor medical assessment
  - donation, adverse reactions to, 52–55, 52t
  - anticoagulant preservative solutions, 50
  - blood collection, 51–52
  - blood containers, 49–50
  - labeling, 49
  - vein selection, 50
  - venipuncture, 51
  - venipuncture site preparation, 50, 50t
- Wiener system, 182, 183t
- Wilson's disease, 535
- Window phase, 158, 421
  - shortening of, 159–160
- Wolff, Andrei, 3
- World Health Organization (WHO), 22
- Worldwide blood supply, 13–15, 14t
- Xenotropic murine leukemia virus related virus (XMRV), 431
- Xg system, 192
- Yersinia enterocolitica*, 106, 389
- Yudin's Institute, 6
- Zika virus, 425–426